A randomized, controlled study of intraarticular injections of etanercept or glucocorticosteroids in patients with rheumatoid arthritis

Submission date	Recruitment status No longer recruiting	Prospectively registered		
15/07/2005		☐ Protocol		
Registration date	Overall study status	Statistical analysis plan		
19/07/2005	Completed	[X] Results		
Last Edited	Condition category	Individual participant data		
05/11/2008	Musculoskeletal Diseases			

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Prof Henning Bliddal

Contact details

The Parker Institute
Frederiksberg Hospital
Frederiksberg
Denmark
DK 2000
+45 38164151
henning.bliddal@fh.hosp.dk

Additional identifiers

EudraCT/CTIS number

IRAS number

 ${\bf Clinical Trials. gov\ number}$

Secondary identifying numbers

KF 02-064/02

Study information

Scientific Title

Study objectives

Etanercept is more efficient than glucocorticosteroid for the treatment of synovitis when given intra-articularly

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Rheumatoid arthritis

Interventions

Intra-articular injection of

- 1. 25 mg Etanercept
- 2. 40 mg methylprednisolone

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Etanercept, glucocorticosteroid

Primary outcome measure

- 1. Patient global evaluation of the joint treated
- 2. Independent joint evaluation by investigator

Secondary outcome measures

Clinical: Joint score for swelling and tenderness and HAQ, CRP, ESR, grip strength Imaging:

Ultrasound Doppler pixel fraction

Ultrasound Doppler RI

Postcontrast magnetic resonance imaging (MRI)

Overall study start date

01/09/2003

Completion date

31/12/2004

Eligibility

Key inclusion criteria

Rheumatoid arthritis (RA), age >18 years, written informed consent, flare of RA in wrist, elbow, or knee joint

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

38

Key exclusion criteria

Systemic anti tumour necrosis factor (TNF) alpha therapy, had had intra-articular injection of steroids in the joint within 3 months, had skin lesions or other disease associated with increased risk of infection after injection, malignancy, severe heart, kidney, and/or lung disease, infections including human immunodeficiency virus (HIV), elevated alanine aminotransferase (ALT) (twice above the reference range), creatinine (>175 mmol/l), leucopenia (<3.5 x $10^9/l$), thrombocytopenia (<125 x $10^9/l$), or hemoglobin <8.5 g/dl, or allergy to the injected compounds. Women were excluded if pregnant, or of childbearing potential with an unacceptable birth control method.

Date of first enrolment 01/09/2003

Date of final enrolment 31/12/2004

Locations

Countries of recruitment

Denmark

Study participating centre The Parker Institute Frederiksberg Denmark DK 2000

Sponsor information

Organisation

The Parker Institute (Denmark)

Sponsor details

Frederiksberg Hospital Ndr Fasanvej 57 Frederiksberg Denmark DK 2000

Sponsor type

Research organisation

Website

http://www.parkerinst.dk

ROR

https://ror.org/05bpbnx46

Funder(s)

Funder type

Industry

Funder Name

Core grant from the Oak Foundation No. OUSA-01-030 (USA)

Funder Name

Wyeth Inc. No. 0881A-101299 (USA)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/09/2006		Yes	No